MedTrace Logo

A Study to Evaluate the Drug-drug Interaction Potential of BMS-986196 in Healthy Participants

NCT05852769 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2023-09-26

No results posted yet for this study

Summary

This study is designed to assess the effect of BMS-986196 on the drug levels of caffeine, montelukast, flurbiprofen, omeprazole, midazolam, digoxin, and pravastatin in healthy participants.

Conditions

  • Healthy Volunteers

Interventions

DRUG

BMS-986196

Specified dose on specified days

DRUG

Caffeine

Specified dose on specified days

DRUG

Montelukast

Specified dose on specified days

DRUG

Flurbiprofen

Specified dose on specified days

DRUG

Omeprazole

Specified dose on specified days

DRUG

Midazolam

Specified dose on specified days

DRUG

Digoxin

Specified dose on specified days

DRUG

Pravastatin

Specified dose on specified days

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-05-31
Primary Completion
2023-08-24
Completion
2023-08-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05852769 on ClinicalTrials.gov